Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Chimerix Inc (NASDAQ: CMRX) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Chimerix Inc (NASDAQ: CMRX) concerning whether a series of statements by Chimerix Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On December 28, 2015, Chimerix Inc disclosed the failure in a Phase 3 study of the Company's lead product candidate, Brincidofovir.

On this news, NASDAQ: CMRX shares declined below $7.00 per share from a closing price of $35.57 on December 24, 2015.

Based in Durham, North Carolina, and founded in 2000 Chimerix Inc is a biopharmaceutical company, engaged in developing and commercializing oral antivirals.

If you purchased shares of Chimerix Inc (NASDAQ: CMRX) on or before December 28, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185